Business Wire

Softomotive Academy Enables the Democratization of RPA with Training at Absolutely No Cost

Share

Softomotive, a leader in robotic process automation solutions, is pleased to announce a refreshed and enlarged RPA Academy. This is a state-of-the-art online learning portal offering comprehensive training in Softomotive’s RPA solutions. It makes it easy for students to join, learn and develop their RPA skills in a fast-moving market where such capabilities are in great demand by current and future employers. It is available at http://academy.softomotive.com.

The Softomotive Academy is designed to improve the employability quotient of professionals and developers. It provides them with the opportunity to develop and deepen their RPA-focused skills which are in short supply at present as enterprises seek to accelerate their digitization efforts and improve productivity.

The e-learning platform provides everyone, including partners and customers, with an intuitive web-based interface that is accessible from any device (including mobile). Once logged in, learners can discover a rich catalogue of video-based tutorials that support on-demand and self-paced learning on Attended and Unattended Automation.

The Softomotive Academy features two different learning paths leading to either Certificates and Diplomas. Upon the successful completion of individual courses, learners will be awarded a Certificate which they can use to advance their careers. Professionals and developers that complete a structured learning program or have practical real-world experience of WinAutomation or ProcessRobot can earn a Diploma by passing a rigorous exam that proves their ability to develop effective and process automations.

“The relaunch of the enlarged Softomotive Academy supports our People 1st approach for RPA which is a new way to deploy RPA and helps to make the democratization of RPA a reality,” says Argyris Kaninis, Co-founder and Chief Operations Officer for Softomotive. “By giving our user community the depth and breadth of knowledge to fully leverage WinAutomation and ProcessRobot, we equip professionals and organizations to accelerate process automation discovery and development.”

The RPA Academy offers detailed, yet easy-to-follow individual courses helping learners to master RPA skills covering attended and unattended automation. Training ranges from a solid foundation on Robotic Desktop Automation (RDA) and enterprise RPA, to the development of complex process automation via scripting, and the advanced management and monitoring of software robots.

Each course consists of short online videos and rich documentation organized into sections. Each section concludes with an interactive quiz, which tests users’ knowledge and skills in RPA. Learners can watch RPA courses at any time tailored for specific roles, or can fully customize their learning experience based on their personal learning objectives.

The curriculum of the Softomotive Academy will be continuously updated, based on learners’ feedback and new product features being added, including new Attended and Unattended Automation content.

The online training site makes it easy to train employees in any organization, without the time and expense involved in face-to-face training. It helps teach the skills needed to implement RPA effectively in a company and to build a solid platform for future personal success while being a member of a rapidly growing global community of RPA professionals.

END

About Softomotive

Softomotive is a leading worldwide provider of Robotic Process Automation solutions, trusted by more than 8,000 companies worldwide.

Softomotive provides the smoothest RPA journey by allowing you to start small, learn quickly and scale seamlessly. This helps to reduce overall project risk and avoids high up-front costs which can make achieving a positive ROI that much harder.

  • WinAutomation is the world’s best desktop automation tool and provides a powerful, robust and easy to use Windows-based platform for building software robots. The desktop version is easily installed on everyone’s computer to accelerate process discovery and development.
  • ProcessRobot is a leading enterprise RPA platform, including enterprise grade security and controls, automation of processes that are generated either top-down or by a bottom-up, People1st Approach.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media enquiries
Softomotive
Bob Weare
Chief Marketing Officer
press@softomotive.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel

Oulu2026 – European Capital of Culture: Oulu to Unveil Full European Capital of Culture 2026 Programme – Live Stream on 4 September 202529.8.2025 11:46:00 EEST | Press release

Hundreds of partners are creating a year in which Northern Finland becomes a new hub of culture. The programme will offer something for everyone: large-scale exhibitions, festivals across all genres, world premieres, performing arts, village celebrations, permanent artworks, sports, and community events across a vast region of 40 municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250829591577/en/ Oulu, with its 39 partner municipalities in Northern Finland, will step into the spotlight as European Capital of Culture 2026. The full programme will be officially launched on Thursday 4 September 2025 in Oulu, streamed live across Europe. The Oulu2026 programme is built around the theme of Cultural Climate Change, meaning a lasting enrichment of cultural life – connecting people through world-class experiences, creativity, and new ways of thinking. “2026 will be a transformative year – for our city, for Northern Finla

Nippon Sanso Holdings Group Unifies Global Brand Logo Launching the "NIPPON SANSO" Brand Worldwide29.8.2025 09:00:00 EEST | Press release

Nippon Sanso Holdings Corporation (President CEO: Toshihiko Hamada) will unify the brand logo for its industrial gas business globally and implement the change in stages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828253560/en/ Until now, our group has operated industrial gas businesses worldwide using the same symbol mark, while adapting to each region. To further enhance recognition and understanding of our group as a unified entity among a broad range of stakeholders, and to maximize corporate value and achieve sustainable growth, we have decided to unify the brand for our industrial gas businesses as "NIPPON SANSO" and standardize the brand logo globally. Moving forward, we will continue striving to be a trusted company for all stakeholders as a globally recognized brand. *Please note that Thermos Group, which operates the consumer household goods business within our group, will not change its brand logo. *The log

TOM FORD Unveils Black Orchid Reserve Campaign Starring Tilda Swinton29.8.2025 07:35:00 EEST | Press release

The quest for exceptional rarity. Introducing Tilda Swinton for the new TOM FORD Black Orchid Reserve campaign. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828507187/en/ “It is a profound honour for me to play a part in the history of TOM FORD’s legendary Black Orchid. Transformation, the blurring of boundaries and the celebration of magical properties have always drawn me close; Black Orchid Reserve is precisely such an enchantment.” — Tilda Swinton A celebrated actor and artist, Swinton is a singular presence known for her fearless artistry and transformative performances. An Academy Award, BAFTA and Golden Lion for Lifetime Achievement winner, Swinton defies conventions with elegance, intellect and a visionary approach to cinema. Her work transcends definition, shaping the culture through work in film, art and performance. TOM FORD creative director Haider Ackermann designed the campaign as a cinematic portrait of r

Novotech Supports Groundbreaking Approval of Anlotinib Combination Therapy for Advanced Soft Tissue Sarcoma28.8.2025 23:15:00 EEST | Press release

Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ Pharma) in achieving a significant regulatory milestone: the approval of Anlotinib Hydrochloride Capsules for a new indication as a first-line treatment for unresectable locally advanced or metastatic soft tissue sarcoma (STS) in combination with chemotherapy. This approval marks the ninth indication for Anlotinib in China and represents the world’s first official approval of an Anlotinib-chemotherapy combination for first-line treatment of advanced or metastatic STS. Previously recommended as a second-line monotherapy by the Chinese Society of Clinical Oncology (CSCO) guidelines, Anlotinib was the only Grade I targeted therapy for STS. This new indication represents a significant advancement for patients who have not previously received systemic treatment, expanding access to more effective and targeted first-line the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye